BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37403252)

  • 1. Deliberative processes in health technology assessment of medicines: the case of Spain.
    Pinilla-Dominguez P; Pinilla-Dominguez J
    Int J Technol Assess Health Care; 2023 Jul; 39(1):e50. PubMed ID: 37403252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-Informed Deliberative Processes for Legitimate Health Benefit Package Design - Part I: Conceptual Framework.
    Baltussen R; Jansen M; Oortwijn W
    Int J Health Policy Manag; 2022 Oct; 11(10):2319-2326. PubMed ID: 34923808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide.
    Oortwijn W; Jansen M; Baltussen R
    Int J Health Policy Manag; 2022 Oct; 11(10):2327-2336. PubMed ID: 34923809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes.
    Baltussen R; Jansen MPM; Bijlmakers L; Grutters J; Kluytmans A; Reuzel RP; Tummers M; der Wilt GJV
    Value Health; 2017 Feb; 20(2):256-260. PubMed ID: 28237205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of new medicines in Spain and comparison with other European countries.
    Epstein D; Espín J
    Gac Sanit; 2020; 34(2):133-140. PubMed ID: 31027840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
    Oortwijn W; Husereau D; Abelson J; Barasa E; Bayani DD; Canuto Santos V; Culyer A; Facey K; Grainger D; Kieslich K; Ollendorf D; Pichon-Riviere A; Sandman L; Strammiello V; Teerawattananon Y
    Value Health; 2022 Jun; 25(6):869-886. PubMed ID: 35667778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
    Oortwijn W; Husereau D; Abelson J; Barasa E; Bayani DD; Santos VC; Culyer A; Facey K; Grainger D; Kieslich K; Ollendorf D; Pichon-Riviere A; Sandman L; Strammiello V; Teerawattananon Y
    Int J Technol Assess Health Care; 2022 Jun; 38(1):e37. PubMed ID: 35656641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deliberative processes in decision making informed by health technology assessment in Latin America.
    Alcaraz A; Pichon-Riviere A; García-Martí S; Alfie V; Augustovski F; Castro H
    Int J Technol Assess Health Care; 2022 Dec; 38(1):e86. PubMed ID: 36524558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology assessment for sexual reproductive health and rights benefits package design in sub-Saharan Africa: A scoping review of evidence-informed deliberative processes.
    Simangolwa WM; Mbonigaba J; Govender K
    PLoS One; 2024; 19(6):e0306042. PubMed ID: 38935794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A health technology assessment of COVID-19 vaccination for Nigerian decision-makers: Identifying stakeholders and pathways to support evidence uptake.
    Uzochukwu BSC; Okeke C; Shuaib F; Torres-Rueda S; Vassall A; Jit M; Nonvignon J; Uzochukwu AC; Ruiz F
    Health Res Policy Syst; 2024 Jun; 22(1):73. PubMed ID: 38926716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
    Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
    Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe.
    Monleón C; Späth HM; Crespo C; Dussart C; Toumi M
    J Mark Access Health Policy; 2022; 10(1):2094047. PubMed ID: 35811835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".
    Gopinathan U; Ottersen T; Cyr PR; Chalkidou K
    Int J Health Policy Manag; 2021 Mar; 10(4):232-236. PubMed ID: 32772012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implicit factors influencing the HTA deliberative processes in 5 European countries: results from a mixed-methods research.
    Monleón C; Martin-Späth H; Crespo C; Dussart C; Toumi M
    Health Policy Open; 2023 Dec; 5():100109. PubMed ID: 38073709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Opportunities for Deliberative Processes for Healthcare Decision-Making Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
    Bond K
    Int J Health Policy Manag; 2023; 12():7458. PubMed ID: 35988028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three Approaches to Improve a Practical Guide on Evidence-Informed Deliberative Processes for Health Benefit Package Design Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
    Guzman J
    Int J Health Policy Manag; 2023; 12():7502. PubMed ID: 36086853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders.
    Wasir R; Irawati S; Makady A; Postma M; Goettsch W; Feenstra T; Buskens E
    PLoS One; 2019; 14(11):e0225626. PubMed ID: 31774854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A situational and stakeholder analysis of health technology assessment in Zimbabwe.
    Dzingirai B; Dambiko P; Matyanga C; Manyau P; Tagwireyi D; Postma MJ; Mafirakureva N; van Hulst M
    Int J Technol Assess Health Care; 2024 Apr; 40(1):e27. PubMed ID: 38679461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.